{"id":32006,"date":"2012-09-25T13:18:46","date_gmt":"2012-09-25T17:18:46","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&#038;p=32006"},"modified":"2012-09-25T13:18:46","modified_gmt":"2012-09-25T17:18:46","slug":"another-one-bites-the-dust-diovan-patent-expires-but-generic-valsartan-is-mia","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2012\/09\/25\/another-one-bites-the-dust-diovan-patent-expires-but-generic-valsartan-is-mia\/","title":{"rendered":"Another One Bites the Dust: Diovan Patent Expires but Generic Valsartan Is MIA"},"content":{"rendered":"<p>Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan HCT, the combination of valsartan and hydrochlorothiazide, was\u00a0<a href=\"http:\/\/investor.mylan.com\/releasedetail.cfm?ReleaseID=708740\">recently launched<\/a>\u00a0by generic drug maker Mylan.<\/p>\n<p><a href=\"http:\/\/www.pharmalot.com\/2012\/09\/a-ranbaxy-puzzle-where-is-the-generic-diovan\/\">As reported on\u00a0<em>Pharmalot<\/em><\/a>, Ranbaxy,\u00a0the embattled generic drug maker, holds the exclusive rights to market generic valsartan for 180 days, but has so far been unable to gain FDA approval. The delay, according to Pharmalot, &#8220;only adds to the uncertainty surrounding Ranbaxy&#8217;s ability to recover from its long-standing manufacturing woes and haggling with the FDA over its ability to resume operations on regular basis in the US.&#8221;<\/p>\n<p>According to\u00a0<a href=\"http:\/\/online.wsj.com\/article\/SB10001424052702303592404577363072539802622.html\">the\u00a0<em>Wall Street Journal<\/em><\/a>, the Diovan franchise generated\u00a0$5.7 billion worldwide in 2011.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Although the patent on valsartan (Diovan, Novartis) expired last Friday, a generic version of the popular antihypertensive drug has yet to make it to market. By contrast, a generic version of Diovan HCT, the combination of valsartan and hydrochlorothiazide, was\u00a0recently launched\u00a0by generic drug maker Mylan. As reported on\u00a0Pharmalot, Ranbaxy,\u00a0the embattled generic drug maker, holds the [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[1480,1477,1479,1478],"class_list":["post-32006","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-antihypertensive-drugs","tag-diovan","tag-generic-drugs","tag-valsartan"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/32006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=32006"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/32006\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=32006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=32006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=32006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}